Valuation: OliX Pharmaceuticals, Inc

Market Cap 2,504B 1.67B 1.46B 1.35B 1.24B 2.36B 159B 2.4B 16.07B 6.31B 78.34B 6.26B 6.12B 269B P/E 2026 *
-79.6x
P/E 2027 * -81.9x
Enterprise Value 2,504B 1.67B 1.46B 1.35B 1.24B 2.36B 159B 2.4B 16.07B 6.31B 78.34B 6.26B 6.12B 269B EV / Sales 2026 *
313x
EV / Sales 2027 * 228x
Free-Float
82.74%
Yield 2026 *
-
Yield 2027 * -
07-08 OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-28 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-04 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-31 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
03-16 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-07 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
12-02 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
11-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
27/08/25 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
14/08/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
15/05/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
1 day+1.48%
1 week-17.48%
Current month-20.82%
1 month-0.88%
3 months-25.24%
6 months-20.26%
Current year-12.25%
1 week 113,000
Extreme 113000
150,800
1 month 113,000
Extreme 113000
179,400
Current year 111,800
Extreme 111800
217,000
1 year 36,350
Extreme 36350
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 31/01/2010
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 27/03/2022
Director TitleAgeSince
Director/Board Member 61 18/03/2019
Director/Board Member 55 18/03/2019
Chairman 54 31/01/2010
Date Insider Type Main position Quantity % Market Cap.
27/02/25Fiscal year

Director

30,000 0.1625%
27/02/25Fiscal year

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%-17.48%+215.90%+723.53% 1.67B
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.88B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.36B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -0.46%-1.12%+68.45%+264.70% 24.29B
Weighted average by Cap. -0.89%-1.51%+52.39%+180.01%

Financials

2026 *2027 *
Net sales 8B 5.33M 4.66M 4.3M 3.97M 7.53M 508M 7.66M 51.36M 20.17M 250M 20M 19.57M 861M 11B 7.33M 6.41M 5.91M 5.46M 10.36M 699M 10.53M 70.62M 27.73M 344M 27.51M 26.91M 1.18B
Net income -31B -20.64M -18.06M -16.66M -15.38M -29.19M -1.97B -29.68M -199M -78.15M -970M -77.51M -75.83M -3.33B -30B -19.98M -17.48M -16.12M -14.89M -28.25M -1.91B -28.72M -193M -75.63M -939M -75.01M -73.38M -3.23B
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
-
Date Price Change Volume
10/07/26 ₩123,200.00 +1.48% 270,094
09/07/26 ₩121,400.00 -0.49% 243,255
08/07/26 ₩122,000.00 -9.43% 422,489
07/07/26 ₩134,700.00 -0.22% 361,760
06/07/26 ₩135,000.00 -9.58% 274,720
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock